Schwartz Gary K (35 results)

Soft cover. Condition: New. 1st Edition. Comic Book. Standard Format and Magazine Sized. First Printing. $2.25 cover price. Color cover by Bill Griffith, back cover by Jay Kinney. NEW. Not read. All corners pointed. Binding tight, without stress creases and square. No tears, creases, bumps or chips. Not marked in any way and very bright, glossy and clean. All comics carefully wrapped and sent boxed. …

Condition: very_good. Gently read. May have name of previous ownership, or ex-library edition. Binding tight; spine straight and smooth, with no creasing; covers clean and crisp. Minimal signs of handling or shelving. 100% GUARANTEE! Shipped with delivery confirmation, if you're not satisfied with purchase please return item! Ships USPS Media Mail.…

Hardcover. Condition: Good. Very Good. Gently used with NO markings in text; binding is tight. Pasadena's finest independent new and used bookstore since 1992.

Condition: New. pp. 296.

Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Soft cover. Condition: Fine. 1st Edition. First edition, first printing of this collection of short stories. SIGNED by 12 of the contributing authors on the title page including Melissa Yi, S.J. Rozan, Kenneth Wishnia, Reed Farrel Coleman (Moe), Jonathan Santlofer, Charles Ardai, Alan Gordon, S.A. Solomon. In fine condition. Signed by Author. …

Condition: New. pp. 296 Illus.

Condition: New. pp. 296.

Condition: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Condition: New. Brand New Original US Edition. Customer service! Satisfaction Guaranteed.

hardcover. Condition: Sehr gut. 294 Seiten; 9781588292001.2 Gewicht in Gramm: 500.

Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Condition: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Condition: New. Brand New! Fast Delivery This is an International Edition and ship within 24-48 hours. Deliver by FedEx and Dhl, & Aramex, UPS, & USPS and we do accept APO and PO BOX Addresses. Order can be delivered worldwide within 6-10 days and we do have flat rate for up to 2LB. Extra shipping charges will be requested if the Book weight is more than 5 LB. This Item May be shipped from India, United states & United Kingdom. Depending on your location and availability.…

Condition: New. In English.

Condition: New. Editor(s): Schwartz, Gary K. Series: Cancer Drug Discovery and Development. Num Pages: 294 pages, biography. BIC Classification: MJCL. Category: (G) General (US: Trade). Dimension: 235 x 155 x 16. Weight in Grams: 456. . 2014. Paperback. . . . .

Condition: New.

Taschenbuch. Condition: Neu. Combination Cancer Therapy | Modulators and Potentiators | Gary K. Schwartz | Taschenbuch | Cancer Drug Discovery and Development | x | Englisch | 2014 | Humana | EAN 9781627038065 | Verantwortliche Person für die EU: Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. …

Condition: New. Editor(s): Schwartz, Gary K. Series: Cancer Drug Discovery and Development. Num Pages: 294 pages, biography. BIC Classification: MJCL. Category: (G) General (US: Trade). Dimension: 235 x 155 x 16. Weight in Grams: 456. . 2014. Paperback. . . . . Books ship from the US and Ireland.

Condition: New. In English.

Condition: New. Reviews those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and details their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. Editor(s): Schwartz, Gary E., Ph.D. Series: Cancer Drug Discovery and Development. Num Pages: 284 pages, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly; (UU) Undergraduate. Dimension: 235 x 155 x 17. Weight in Grams: 1310. . 2004. Hardback. . . . . …

Paperback. Condition: Like New. Like New. book.

Gebunden. Condition: New. Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interactio.

Condition: New. Reviews those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and details their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. Editor(s): Schwartz, Gary E., Ph.D. Series: Cancer Drug Discovery and Development. Num Pages: 284 pages, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly; (UU) Undergraduate. Dimension: 235 x 155 x 17. Weight in Grams: 1310. . 2004. Hardback. . . . . Books ship from the US and Ireland. …

Buch. Condition: Neu. Neuware - Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy. Early clinical trials of the new molecular-based anticancer agents have shown that many are marginal in controlling cancer, but prove to be potent modulators and potentiators of chemotherapy-induced apoptosis when used in combination with classic cytotoxic drugs or radiation. In Combination Cancer Therapy: Modulators and Potentiators, expert physician-scientists and clinicians with first-hand experience in the clinical development of targeted therapies review those combinations that hold the most promise for the future of medical oncology, detailing their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory benchtop to the patient's bedside as a new generation of cancer therapeutics. Cutting-edge and forward-looking, Combination Cancer Therapy: Modulators and Potentiators offers everyone in the fields of cancer drug development and therapy a powerful new understanding of the optimal sequencing and scheduling of new combination drug therapies necessary to maximize the effects for cancer patients today.…

Gebonden. Condition: Boek goed. Dust Jacket Condition: Stofomslag. 344 pp. Afbeeldingen en catalogus van alle werken. Overzicht van alle documenten. met 275 afbeeldingen, waarvan 55 in kleur.

Condition: new. Questo è un articolo print on demand.

Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy. 296 pp. Englisch.…